Insider Transactions in Q2 2024 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Eric Devroe Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.64%
|
$10,000
$1.04 P/Share
|
|
May 14
2024
|
Katharine Peterson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-2.05%
|
$792
$8.36 P/Share
|
|
May 14
2024
|
Rasmus Holm Jorgensen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-1.33%
|
$2,944
$8.36 P/Share
|
|
May 14
2024
|
Kristina Masson EVP - Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
490
-0.15%
|
$3,920
$8.36 P/Share
|
|
May 14
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
184
-0.46%
|
$1,472
$8.36 P/Share
|
|
May 14
2024
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
54,918
-2.1%
|
$439,344
$8.36 P/Share
|
|
May 14
2024
|
Eric Devroe Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
613
-1.03%
|
$4,904
$8.36 P/Share
|
|
May 14
2024
|
Erick Gamelin Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
402
-2.21%
|
$3,216
$8.36 P/Share
|
|
Apr 17
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.38%
|
$5,580
$10.34 P/Share
|
|
Apr 11
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,530,000
+30.85%
|
$28,240,000
$8.5 P/Share
|
|
Apr 11
2024
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,353,000
+30.5%
|
$18,824,000
$8.5 P/Share
|